[Market Feature] Lameditech Soars 29% on Medical Device Approval News

Following the announcement that the Ministry of Food and Drug Safety has approved Lameditech's personal laser lancing and blood glucose monitoring combo device, the company's stock price surged by around 29%.

As of 9:16 a.m. on March 11, Lameditech was trading at 5,920 won, up by 29.97% (1,365 won) from the previous trading day.

On March 11, Lameditech announced that it had received product approval from the Ministry of Food and Drug Safety for its personal laser lancing and blood glucose monitoring combo device, "HandyRay-Glu." HandyRay-Glu is a product designed to simultaneously address the issues of pain, hygiene, and portability, which have been pointed out as limitations of existing blood glucose meters.

Lameditech secured a manufacturing license for export in vitro diagnostic medical devices in December of last year, and with this latest product approval from the Ministry of Food and Drug Safety, the company can now begin full-scale manufacturing and sales in the domestic market.

Lameditech is also aiming to expand into overseas markets with HandyRay-Glu. The device received significant attention from Europe and Japan at MEDICA 2025, the world's largest medical device exhibition.

This content was produced with the assistance of AI translation services.